Frontiers in Pediatrics

Front Pediatr. 7: 458

Progressive Liver Disease in Patients With Ataxia Telangiectasia

Helena Donath¹*, Sandra Woelke¹, Marius Theis², Ursula Heß¹, Viola Knop³, Eva Herrmann⁴, Dorothea Krauskopf², Matthias Kieslich², Ralf Schubert¹, Stefan Zielen¹

¹Division of Allergology, Department for Children and Adolescents, Pulmonology and Cystic Fibrosis, Goethe University, Frankfurt, Germany

²Division of Pediatric Neurology, Department for Children and Adolescents, Goethe University, Frankfurt, Germany

³Department for Internal Medicine, Goethe University, Frankfurt, Germany

⁴Institute of Biostatistics and Mathematical Modeling, Goethe University, Frankfurt, Germany

Edited by: Enrico Baruffini, University of Parma, Italy

Reviewed by: Nelson L. S. Tang, The Chinese University of Hong Kong, China; Luciana Chessa, Sapienza University of Rome, Italy

*Correspondence: Helena Donath helena.pommerening@kgu.de

This article was submitted to Genetic Disorders, a section of the journal Frontiers in Pediatrics

Copyright © 2019 Pommerening,Woelke, Theis, Heß, Knop, Herrmann, Krauskopf, Kieslich, Schubert and Zielen.

DOI: 10.3389/fped.2019.00458

Published online: 07 November 2019

Abstract

Ataxia telangiectasia (A-T) is a devastating multi-system disorder characterized by progressive cerebellar ataxia, immunodeficiency, genetic instability, premature aging and growth retardation. Due to better care the patients get older than in the past and new disease entities like disturbed glucose tolerance and liver disease emerge. The objective of the present investigation is to determine the evolution of liver disease and its relation to age and neurological deterioration. The study included 67 patients aged 1 to 38 years with classical A-T. At least two measurements of liver enzymes were performed within a minimum interval of 6 months in 56 patients. The median follow-up period was 4 years (1–16 years). A total of 316 liver enzyme measurements were performed. For analysis, patients were divided into two age groups (Group 1: <12 years; group 2: ≥12 years). In addition, ultrasound of the liver and Klockgether Ataxia Score (KAS) were analyzed. We found significantly higher levels of alpha-fetoprotein (AFP) (226,8 ± 20.87 ng/ml vs. 565,1 ± 24.3 ng/ml, p < 0.0001), and liver enzymes like ALT (23.52 ± 0.77 IU/L vs. 87.83 ± 5.31 IU/L, p < 0.0001) in patients in group 2. In addition, we could show a significant correlation between age and AFP, GGT, and KAS. Ultrasound revealed hepatic steatosis in 11/19 (57.9%) patients in group 2. One female patient aged 37 years died due to a hepato-cellular carcinoma (HCC). Liver disease is present in the majority of older A-T patients. Structural changes, non-alcoholic fatty liver disease and fibrosis are frequent findings. Progress of liver disease is concomitant to neurological deterioration.

Introduction

Ataxia telangiectasia (A-T) is a rare devastating human autosomal recessive disorder characterized by progressive cerebellar ataxia, immunodeficiency, growth retardation, chromosomal instability, and cancer susceptibility (1–3). Recurrent respiratory infections and cancer are the major reasons for death in A-T (4, 5). Due to better care, the majority of patients get older than in the past and new disease entities like disturbed glucose tolerance and liver disease emerge (6). Disease progression of A-T is evident at different organ systems. Neurological decline, progressive lung disease and, recently, metabolic alterations, and liver disease have been described as prominent features (6, 7). Still, little is known about the natural course of hepatopathy in A-T. Liver enzymes such as gamma-glutamyl-transferase (GGT), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) are elevated in older patients, suggesting hepatic dysfunction (8). In addition, high levels of alpha-fetoprotein (AFP) are characteristic findings among affected patients at all ages. Normally, AFP production in the fetal liver ceases after embryonal differentiation until the age of one (9), whereas in A-T it is slowly increasing with age (10). Remarkably, post-mortem analyses of the liver in A-T patients showed severe pathological findings like hepatitis with periportal fibrosis (11) or even cirrhosis (12). There are few clinical case reports on histological finding of non-alcoholic steatosis hepatis (NASH), liver cirrhosis and hepato-cellular carcinoma (HCC) in A-T (7, 13, 14). The first cohort study of prevalence and nature of hepatic involvement in patients with A-T was published recently by Weiss et al. (7). The authors reported that abnormal liver enzymes were present in 43.4% of A-T patients. In addition, dyslipidemia with increased total cholesterol and triglycerides was detected in some older patients (6, 7). A recent study from Paulino et al. (15) in 17 A-T patients reported that diabetes and liver disease is demonstrable by atherosclerotic lipid profiling; in addition they found hepatic steatosis in 64.7% of their patients which tends to get worse as they become older. Some of the patients suffer from metformin-resistant diabetes, which typically occurs from adolescence on (2, 6). However, reduced insulin sensitivity and dysglycemia can also be observed in A-T patients without evident diabetes (15, 16). There is growing evidence for a correlation between dyslipidemia, insulin resistance and the development of a fatty liver disease (7, 15). Still, the search for a possible etiology of liver disease (virus serology, autoantibodies, iron, copper metabolism, alpha-1-antitrypsin, C-reactive protein (CRP), thyroid function test) in A-T did not show significant findings (7). Thus, liver disease progression may be caused intrinsically by multiple factors of which inflammation and oxidative stress may be of particular importance (17–20).

Apart from these investigations, literature is still scarce on liver involvement in A-T. Although not investigated in previous studies, it can be speculated that liver disease indicates a more severe course of A-T, going along or maybe even aggravating neurological decline. In general, liver disease leads to accumulation of toxic metabolites, e.g., ammoniac, which harms the nervous system. It is well known for decades that there is a relationship between normal liver cell function and brain (21–23). Pruritus in cholestasis patients and profound fatigue are often described in chronic liver disease and both symptoms are commonly reported by older A-T patients (1, 2).Nevertheless, the relationship between fatigue, pruritus and liver disease is unclear and may be in part due to premature aging of the skin and not caused by liver disease.

In this investigation we aimed to characterize not only the evolution of liver disease by liver enzymes, CRP, abdominal ultrasound but also its relation to the neurological status studied by Klockgether Ataxia Score (KAS) in a large cohort of A-T patients.

Materials and Methods

In a retrospective analysis from August 2002 to August 2018 we studied data of 67 classical A-T patients from the Frankfurt A-T cohort aged 1 to 38 years regarding CRP, liver enzymes (GGT, ALT, AST), abdominal ultrasound and neurological status according to the KAS (24). Longitudinal data were available of 56 patients. All patients were clinically and/or genetically diagnosed with A-T according to recent World Health Organization (WHO) recommendations.

We compared patients <12 years of age (group 1, n = 37) to patient ≥12 years (group 2, n = 30). Patients with longitudinal data in both groups were assigned to the group for which more measurements were available.

Patients who had experienced chemotherapy and/or stem cell transplantation (n = 5) were excluded from the record after treatment. A total of 143 measurements were included in group 1, 173 in group 2.

Data Ascertainment

The data presented were collected from two non-interventional clinical trials at the children's hospital Frankfurt. Both trials were registered at clinicaltrials.gov 2012 (Susceptibility to infections in ataxia telangiectasia; NCT02345135) and 2017 (Susceptibility to Infections, tumor risk, and liver disease in patients with ataxia telangiectasia; NCT03357978). The study was approved by the responsible ethics committee in Frankfurt (application number 504/15 and 121/12).

The study was conducted following the ethical principles of the Declaration of Helsinki, regulatory requirements and the code of Good Clinical Practice.

Blood Analysis

AFP, GGT, AST, ALT, CRP, cholesterol, and triacylglycerol (TAG) were determined in the serum of whole blood from a total of 67 patients. We used our data base to collect the parameters retrospectively. In case of multiple blood results within <6 months, the median within that period of time was taken into consideration.

Ultrasound

Abdominal ultrasound was performed by a pediatric radiologist (group 1 and group 2). The reports were taken from our data base.

Neurological Assessment

All A-T patients (group 1 and group 2) were examined by a pediatric neurologist as recently described (25). Disease progression was classified according to KAS (24). Gait ataxia, standing ataxia, ataxia of the upper and lower extremity, dysarthria, intention tremor and dysdiadochokinesis were assessed. Impairment is evaluated in points from zero (nonexistent) to five (maximum deficiency) so that the maximum score is 35 points.

Statistical Analysis

For statistical analysis GraphPad Prism 5.01 (GraphPad Software, Inc.) and R version 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria) were used. Values are presented as arithmetic means with standard deviations (SDs). For comparisons between the two study groups, two-tailed Mann- Whitney- U-test was applied. Correlations were analyzed by Spearman's correlation coefficient. Liver enzymes (ALT, AST, GGT) were defined as primary variables. The secondary variables included AFP, CRP, cholesterol, and TAG and KAS. In addition, a multivariable linear mixed effect regression analysis was performed and normality assumptions for residuals were checked for this analysis.

P-values ≤ 0.05 were considered significant.

Results

We investigated 67 patients with A-T for liver disease. Patients were divided according to age into two groups (group 1: 37 patients aged <12 years, group 2: 30 patients ≥12 years). At least two measurements of liver enzymes were performed within a minimum interval of 6 months in 56 patients (longitudinal data). The median follow-up period was 4 years (1–16 years). A total of 316 liver enzyme measurements were performed.

Figures 1, 2 show the comparison between group 1 and 2 concerning GGT and ALT. Figures 3, 4 show individual courses of GGT and ALT with age.

Figure 1View larger versionFigure 1. Comparison of GGT [U/L] between A-T patient <12 years of age (n = 127) and ≥12 years of age (n = 156). Graph is shown as logarithmic scale p < 0.0001.

Figure 2View larger versionFigure 2. Comparison of ALT [U/L] between A-T patient <12 years of age (n = 138) and ≥12 years of age (n = 164). Graph is shown as logarithmic scale p < 0.0001.

Figure 3View larger versionFigure 3. Individual course of GGT with age, the scattered area is the normal range for GGT.

Figure 4View larger versionFigure 4. Individual course of ALT with age, the scattered area is the normal range for ALT.

Table 1 shows patient characteristics. The mean age was 6.1 years in group 1 and 18.4 years in group 2 (p < 0.0001). We found significantly higher levels of AFP (226.8 ± 20.87 ng/ml vs. 565.1 ± 24.3 ng/ml, p < 0.0001), GGT (12.98 ± 0.41 IU/L vs. 149.5 + 10.99, p < 0.0001) and ALT (23.52 ± 0.77 IU/L vs. 87.83 ± 5.31 IU/L, p < 0.0001) in older A-T patients. The analysis of AST did not show a significant difference (37.92 ± 0.75 IU/L vs. 59.72 ± 3.52 IU/L, p >0.05). In addition to that, CRP levels were significantly increased in the older group (0.16 ± 0.03 vs. 0.27 ± 0.04, p < 0.05) pointing to a chronic systemic inflammatory response, especially in older patients.

See full tableTable 1. Patients' characteristics.

TAG and cholesterol were significantly higher in group 2 when compared to group 1 (TAG: group 1: 84.39 ± 8.0 vs. group 2: 251.8 ± 22,24, p < 0.0001; cholesterol: group 1 176.3 ± 5.13; group 2: 212.7 ± 7.91, p < 0.05).

We could show a significant correlation between age and AFP (r = 0.64, p < 0.0001), membrane-bound GGT (r = 0.82, p < 0.0001) and cytoplasmic ALT (r = 0.63, p < 0.0001). In addition, CRP (r = 0.38, p < 0.01), TAG (r = 0.5, p < 0.01) and cholesterol (r = 0.46, p < 0.01) correlated with age. Mitochondrial AST (r = 0.024) did not correlate with age. Correlations are shown in Table 2.

See full tableTable 2. Linear Regression of AFP, GGT, ALT, AST, KAS, TAG, cholesterol, and CRP with age.

A significant correlation could be established between GGT and HbA1c (r = 0.61, p < 0.0001), cholesterol (r = 0.59, p < 0.0001), TAG (r = 0.61, p < 0.0001).The progressive elevation of liver enzymes is shown in Figure 5 and Table 3.

Figure 5View larger versionFigure 5. Liver enzyme elevation in percent of affected patients with age.

See full tableTable 3. Dataset on evolution of liver enzymes with age.

We analyzed 57 KAS in group 1 and 42 in group 2. KAS differed significantly with 12.92 ± 0.86 points vs. 23.76 ± 0.43 points, p < 0.0001. As expected, KAS score correlated significantly with age (r = 0.76, p < 0.0001). We could also show a significant correlation between KAS and AFP (r = 0.47, p < 0.0001) and GGT (r = 0.62) and ALT (r = 0.46). No correlation was found between KAS and AST. In addition, the multivariable linear mixed effect regression analysis showed that age and GGT were independent significant predictors for KAS. A total of 92 abdominal ultrasounds were performed. In group 1, 26 patients had undergone a total of 35 examinations. In group 2, 19 patients had performed a total of 57 examinations. Ultrasound revealed hepatic steatosis in 11/19 (57.9%) patients in group 2 and in none of the younger patients. The presence of fatty liver disease correlated significantly with age (r = 0.59, p < 0.0001). Four patients had ultrasounds analyzed in both, group 1 and 2. Twenty-one patients in both groups were never investigated with ultrasound.

One female patient aged 37 years died due to a HCC.

Discussion

A-T is a devastating systemic disease characterized by neurodegeneration, increased risk for cancer, immunodeficiency and failure to thrive. Whereas, immunodeficiency in patients is rather static, disease progression is demonstrable at different organ systems. Liver disease was recently discovered as a new entity, and underlies progression to liver cirrhosis or HCC (7, 15).

Many of the clinical alterations in A-T are related to dysfunctional control of ROS observed in the absence of Ataxia telangiectasia mutated (ATM) (17, 26). In addition, early insulin resistance and a high prevalence of diabetes type 2 in older patients depend on this process (6). While gastrointestinal involvement, mainly dysphagia, poor weight gain, and failure to thrive have been well documented (1, 2, 27), hepatic and metabolic involvement in A-T is little known and understood (6, 7, 15). In this investigation we measured liver enzymes in 67 patients and had longitudinal data of 56 patients. We were able to show that GGT and ALT were significantly increased in older compared to younger patients. The mitochondrial AST was not significantly different, elevated enzyme levels of AST point to a severe hepatic damage. Elevated GGT, ALT, and AST levels were not present in group 1. In group 2 we could show the evolution of liver enzymes with age after puberty as shown in Figure 5 and Table 2. We could demonstrate a constant increase of liver enzymes after the 12th year of life up to 92.9% in the third decade of life.

For group 2, these data are in line with the recent reports of the National center in Israel and Brazil which found liver enzyme abnormalities in 43% of children and in 64% of older A-T patients (6, 15). The report from Brazil by Paulino et al. concluded that the increase in age is a risk factor for insulin resistance and liver involvement (15).

Our investigation is the first investigation of the evolution of liver disease and neurological decline longitudinally over 4 years (median, 1–16 years) in 67 patients. We could show that liver enzymes increased constantly after puberty. As expected, liver enzymes detected in the serum correlate well with the extent of liver disease. In addition to that we could demonstrate a correlation between age and liver disease (GGT, r = 0.82) as well as KAS (r = 0.76). A multivariate analysis confirmed the correlation of age and GGT with KAS. Of course neurodegeneration is present long before other organ systems show significant dysfunction. This concerns liver, lungs, pancreas, malignancy, and blood vessels. Our assumption is that in addition to the toxic effects on the (central) nervous system, liver involvement indicates progression of the disease as it affects one of the most regenerative and hard-wearing organs in the human body. In summary, according to the present data, we assume that patients with liver disease show a higher severity of A-T which is due to a potentially accelerated neurodegeneration and higher risk for HCC.

The available data show that GGT is the most sensitive marker and the first to increase in case of liver disease. This is logically explained by the location of GGT in the cell membrane. GGT is expressed by liver and bile tissue, but can also be found in kidney, pancreas and spleen. Therefore, it is not as specific as AST and ALT. However, most parts of serum GGT originate from the liver. Perishing hepatocytes initially set the membrane-bound GGT free. Only in severe damage the cytoplasmic ALT and lastly the mitochondrial AST will be released to plasma.

In the search for potential other risk factors of liver disease than age, we could show a significant correlation for HbA1c (r = 0.61, p < 0.0001), cholesterol (r = 0.59, p < 0.0001), TAG (r = 0.61, p < 0.0001) with GGT. CRP and IgM did not correlate.

This highlights the role of metabolic risk factors in development of liver disease. Cholesterol, elevated lipid levels and diabetes lead to fatty liver disease. We could not demonstrate a correlation between immunological findings and liver disease. Much more, our data suggest that liver disease and metabolic alterations are inherent in the ATM gene.

Apart from liver enzymes, we analyzed abdominal ultrasounds of the Frankfurt A-T cohort for fatty liver disease. In group 1, no patient was affected, whereas almost 60% of our older patients were affected. In addition, there was a pronounced progression of steatosis with age. One female patient died at the age of 37 due to HCC.

There have been several reports on non-alcoholic fatty liver disease (NAFLD), NASH, and liver cirrhosis as well as portal hypertension in A-T patients (7, 12, 13). NASH is histologically characterized by steatosis, swollen hepatocytes, inflammation, and fibrosis in the lobe area. With persistent necro-inflammatory inflammation and increasing liver damage, patients with NASH often develop liver fibrosis (28–30). Cirrhosis is the major clinical endpoint in NASH. Most likely A-T patients have a high risk to develop fibrotic and cirrhotic changes since ongoing inflammation with high levels of IL-6 and IL-8 have been detected before (19, 31). Chronic systemic inflammation and misled immune response as observed in granuloma and premature aging are well known features in A-T patients (2, 32, 33). Although we did not measure cytokines in our patients, mild elevated CRP levels in our older patients indicated permanent inflammatory response and acute phase reaction. The potential for NASH to progress to both, cirrhosis and later HCC, has been known for decades, but the underlying molecular mechanism in A-T patients is not elucidated so far.

Of course, metabolic imbalance, reduced glucose tolerance, and dyslipidemia cause NAFLD. In addition, oxidative stress seems to play a major role in the development and progression of liver disease. ATM can be activated by ROS directly, or by DNA double-strand breaks (34). In the absence of ATM, patients show low antioxidant capacities (26). As a result, macromolecules, lipids and DNA are exposed to permanent oxidative stress and resulting damage (17). Similar results could be shown in NASH, where oxidative stress and lipid peroxidation are increased as well (35). There is emerging evidence that the ATM signaling pathway plays a crucial role in the response to the accumulation of fat in the liver as demonstrated in mice (36). Hepatic fat accumulations as well as oxidative stress from free fatty acids activate ATM. In turn, p53 activates the pro-apoptotic gene “p53 upregulated modulator of apoptosis” (PUMA). PUMA is a major player in development of steatoapoptosis in hepatocytes (36). Since apoptosis of hepatocytes normally correlates with the severity of NASH and the stage of fibrosis, it can be assumed that steatoapoptosis is also responsible for the progression of the liver disease (1, 36, 37).

Fatigue is a well-documented phenomenon of any kind of liver disease (38). The chronic fatigue observed in older A-T patients may also result from liver involvement.

Moreover, the alterations of lipid metabolism biomarkers are suggestive of atherosclerotic risk of A-T patients and emphasize the importance of multidisciplinary care, routine monitoring of cardiovascular biomarkers and appropriate nutritional guidance (1, 7, 15). Recently, it was shown that ATM is also involved in metabolic and cardiovascular complications when disrupted (39, 40). In addition, ATM kinase deficiency aggravated left ventricular dysfunction and remodeling late after myocardial infarction in mice (41). Interestingly, mice with ATM haplo-deficiency had decreased vascular endothelial growth factor production and impaired angiogenesis in response to myocardial infarction, leading to accelerated heart failure (41). Indeed there is a first report which found that the atherosclerotic lipid profiling was correlated to carotid intima-media thickness in A-T patients (15). In line with this finding is an increased of cardiovascular events A-T heterozygotes reported in several studies (40, 42).

The limitations of the present study are its retrospective character, in addition to that only the KAS was used to assess neurological decline. However, the more sophisticated SARA score was only introduced in 2006 and was therefore not available for all patients.

Conclusion

Liver disease is present in the majority of adolescents with A-T, starting after the 12th year of life. Abnormal ultrasound, elevated liver enzymes, alterations of lipid metabolism and elevated CRP suggest an atherosclerotic risk in A-T. Besides the enormous threat of progression of NASH to liver cirrhosis and HCC, liver disease may indicate a more severe disease course and aggravate neurological symptoms. Thus, prevention of liver disease is of particular importance for better well-being, better life quality and exercise endurance of our patients.

What This Study Adds to the Field

Liver disease is present in almost all older A-T patients and begins in puberty. Structural changes, non-alcoholic fatty liver disease and fibrosis are frequent findings. Liver disease may indicate a more severe disease course and aggravate neurological symptoms.

Data Availability Statement

The datasets analyzed in this manuscript are not publicly available. Requests to access the datasets should be directed to helena.pommerening@kgu.de.

Ethics Statement

The studies involving human participants were reviewed and approved by Ethics committee Goethe University Clinic Frankfurt. Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin.

Author Contributions

HD helped with the study design, conducted visits, collected data, did statistical analysis, and wrote the manuscript. SZ developed the study design, conducted visits, and wrote the manuscript. SW conducted visits, collected data, and helped with the study design. RS collected data, helped with statistical analysis, and helped developing the study design. MK and MT evaluated KAS (neurological visits). UH helped collecting data and writing the manuscript. DK helped collecting data. VK helped collecting and interpreting data. EH did the statistical review.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Glossary

Abbreviations

A-T

Ataxia telangiectasia

GGT

Gamma-glutamyl-transferase

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

AFP

Alpha feto-protein

NASH

Non-alcoholic steatosis hepatis

HCC

Hepato-cellular carcinoma

CRP

C-reactive protein

KAS

Klockgether ataxia score

WHO

World Health Organization

TAG

Triacylglycerol

SD

Standard deviation

ROS

Reactive oxygen species

ATM

Ataxia telangiectasia mutated

NAFLD

Non-alcoholic fatty liver disease

PUMA

P53 upregulated modulator of apoptosis.

Articles from Frontiers in Pediatrics are provided here courtesy of Frontiers Media SA

PMC Copyright Notice

The articles available from the PMC site are protected by copyright, even though access is free. Copyright is held by the respective authors or publishers who provide these articles to PMC. Users of PMC are responsible for complying with the terms and conditions defined by the copyright holder.

Users should assume that standard copyright protection applies to articles in PMC, unless an article contains an explicit license statement that gives a user additional reuse or redistribution rights. PMC does not allow automated/bulk downloading of articles that have standard copyright protection.

See the copyright notice on the PMC site, https://www.ncbi.nlm.nih.gov/pmc/about/copyright/, for further details and specific exceptions.

References

H PommereningS van DullemenM KieslichR SchubertS ZielenS Voss. Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study. Orphanet J Rare Dis. (2015) 10:526. 10.1186/s13023-015-0373-z26645295

C Rothblum-OviattJ WrightMA Lefton-GreifSA McGrath-MorrowTO CrawfordHM Lederman. Ataxia telangiectasia: a review. Orphanet J Rare Dis. (2016) 11:15. 10.1186/s13023-016-0543-726879382

S VossJ PietznerF HocheAMR TaylorJI LastR Schubert. Growth retardation and growth hormone deficiency in patients with Ataxia telangiectasia. Growth Factors. (2014) 32:123–29. 10.3109/08977194.2014.93980525060036

SA SchroederS Zielen. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol. (2014) 49:389–99. 10.1002/ppul.2281723761391

R MicolL Ben SlamaF SuarezL Le MignotJ BeautéN Mahlaoui. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol. (2011) 128:382–9.e1. 10.1016/j.jaci.2011.03.05221665257

A NissenkornY Levy-ShragaY Banet-LeviA LahadI SaroukD Modan-Moses. Endocrine abnormalities in ataxia telangiectasia: findings from a national cohort. Pediatr Res. (2016) 79:889–94. 10.1038/pr.2016.1926891003

B WeissA KrauthammerM SoudackA LahadI SaroukR Somech. Liver disease in pediatric patients with Ataxia Telangiectasia. J Pediat Gastroenterol Nutri. (2016) 62:550–55. 10.1097/MPG.000000000000103626594831

T GüngörI BühringR CremerM GartenschlägerS Zielen. Pathogenesis, diagnosis, clinical and therapeutic aspects of ataxia telangiectasia. Klinische Pädiatrie. (1997) 209:328–35. 10.1055/s-2008-10439729411043

J SchievingM de VriesJ van VugtC WeemaesM van DeurenJ Nicolai. Alpha-fetoprotein, a fascinating protein and biomarker in neurology. Eur J Paediat Neurol. (2014) 18:243–48. 10.1016/j.ejpn.2013.09.00324120489

TA WaldmannKR McIntire Serum-Alpha-feto-protein-levels in Patients with Ataxia telangiectasia. Lancet. (1972) 2:1112–5. 10.1016/S0140-6736(72)92717-14117204

LH PillsburySM PetersRL WientzenT PhillipsZL PapadopoulouJA Bellanti Ataxia telangiectasia: immunologically mediated renal and hepatic failure. Ann Allergy. (1985) 55:539–40, 593–8.

M CasarilGB GabrielliF CapraGC Falezza [Ataxia telangiectasia. Description of a case with multiple cerebral hemorrhages and liver cirrhosis]. Minerva Med. (1982) 8:2183–8.

MM PatilSVI Patil Ataxia telangiectasia with Hepatocellular Carcinoma. Arch Pathol Lab Med. (1985) 109:1000–4.2996458

T CaballeroM Caba-MolinaJ SalmerónM Gómez-Morales. Nonalcoholic steatohepatitis in a patient with Ataxia-Telangiectasia. Case Rep Hepatol. (2014) 2014:1–5. 10.1155/2014/76125025374730

TL PaulinoMN RafaelS HixDC ShigueokaSA AjzenC Kochi. Is age a risk factor for liver disease and metabolic alterations in ataxia Telangiectasia patients? Orphanet J Rare Dis. (2017) 12:4036. 10.1186/s13023-017-0689-y28778179

PJ ConnellyN SmithR ChadwickAR ExleyJM ShneersonER Pearson. Recessive mutations in the cancer gene Ataxia Telangiectasia Mutated (ATM), at a locus previously associated with metformin response, cause dysglycaemia and insulin resistance. Diabet Med. (2016) 33:371–75. 10.1111/dme.1303726606753

J ReichenbachR SchubertD SchindlerK MüllerH BöhlesS Zielen. Elevated oxidative stress in patients with Ataxia Telangiectasia. Antioxid Redox Signal. (2002) 4:465–69. 10.1089/1523086026019625412215213

Y YangCW HuiJ LiK HerrupJE Khoury. The interaction of the Atm genotype with inflammation and oxidative stress. PLoS ONE. (2014) 9:e85863. 10.1371/journal.pone.008586324465754

SA McGrath-MorrowJM CollacoTO CrawfordKA CarsonMA Lefton-GreifP Zeitlin. Elevated serum IL-8 levels in Ataxia Telangiectasia. J Pediat. (2010) 156:682–4.e1. 10.1016/j.jpeds.2009.12.00720171651

M Zaki-DizajiSM AkramiG AziziH AbolhassaniA Aghamohammadi. Inflammation, a significant player of Ataxia–Telangiectasia pathogenesis? Inflamm. Res. (2018) 67:559–70. 10.1007/s00011-018-1142-y29582093

I Castilla-CortázarM García-FernándezG DelgadoJE PucheI SierraR Barhoum. Hepatoprotection and neuroprotection induced by low doses of IGF-II in aging rats. J Transl Med. (2011) 9:103. 10.1186/1479-5876-9-10321733157

PN RenjenL KhannaR RastogiNI Khan. Acquired hepatocerebral degeneration. BMJ Case Rep. (2013) 2013. 10.1136/bcr-2013-00938723780767

C McDonaldJ NewtonHM LaiSN BakerDE Jones. Central nervous system dysfunction in primary biliary cirrhosis and its relationship to symptoms. J Hepatol. (2010) 53:1095–100. 10.1016/j.jhep.2010.05.03620810186

T KlockgetherG SchrothHC DienerJ Dichgans. Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatr. (1990) 53:297–305 10.1136/jnnp.53.4.2972341843

M KieslichF HocheJ ReichenbachS WeidauerL PortoS Vlaho. Extracerebellar MRI—lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced Age. Cerebellum. (2010) 9:190–97. 10.1007/s12311-009-0138-019898915

J ReichenbachR SchubertC SchwanK MüllerHJ BöhlesS Zielen. Anti-oxidative capacity in patients with ataxia telangiectasia. Clin Exp Immunol. (1999) 117:535–9. 10.1046/j.1365-2249.1999.01000.x10469059

S WoelkeH PommereningM KieslichR SchubertS Zielen. Growth hormone treatment in patients with ataxia telangiectasia. Growth Factors. (2017) 35:125–130. 10.1080/08977194.2017.136768128948852

BruntPD BerkMI FielSN Thung. Nonalcoholic Steatohepatitis. Semin Liver Dis. (2004) 24:3–20. 10.1055/s-2004-82309815085483

EM BruntVW WongV NobiliCP DayS SookoianJJ Maher Nonalcoholic fatty liver disease. Nat Rev Dis Primers. (2015) 24:15080 10.1038/nrdp.2015.80

D KleinerE Brunt. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis. (2012) 32:3–13. 10.1055/s-0032-130642122418883

SA McGrath-MorrowJM CollacoB DetrickHM Lederman. Serum interleukin-6 levels and pulmonary function in Ataxia-Telangiectasia. J Pediat. (2016) 171:256–61.e1. 10.1016/j.jpeds.2016.01.00226851119

S WoelkeE ValeskyS BakhtiarH PommereningLM PfeffermannR Schubert. Treatment of granulomas in patients with Ataxia Telangiectasia. Front Immunol. (2018) 9:2000. 10.3389/fimmu.2018.0200030279689

Y ShilohHM Lederman. Ataxia-telangiectasia (A-T): an emerging dimension of premature ageing. Ageing Res Rev. (2017) 33:7–88. 10.1016/j.arr.2016.05.00227181190

Z GuoR DeshpandeTT Paull. ATM activation in the presence of oxidative stress. Cell Cycle. (2010) 9:4805–11. 10.4161/cc.9.24.1432321150274

M RG Parola. Oxidative stress-related molecules and liver fibrosis. J Hepatol. (2001) 35:297–306. 10.1016/S0168-8278(01)00142-811580156

EK DaugherityG BalmusA Al SaeiES MooreD Abi AbdallahAB Rogers. The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle. (2014) 11:1918–28. 10.4161/cc.2025922544329

D SchuppanR SurabattulaXY Wang. Determinants of fibrosis progression and regression in NASH. J Hepatol. (2018) 68:238–50. 10.1016/j.jhep.2017.11.01229154966

EA Jones. Fatigue associated with chronic liver disease: a riddle wrapped in a mystery inside an enigma. Hepatology. (1995) 22:1606–08. 10.1002/hep.18402205387590682

IGA AndradeBT Costa-CarvalhoR da SilvaS HixC KochiFI Suano-Souza. Risk of atherosclerosis in patients with Ataxia Telangiectasia. Ann Nutr Metab. (2015) 66:196–201. 10.1159/00043079026045095

N van OsN RoeleveldC WeemaesM JongmansG JanssensA Taylor. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. (2016) 90:105–17. 10.1111/cge.1271026662178

LL DanielSLC ScofieldP ThrasherS DalalCR DanielsCR Foster. Ataxia telangiectasia-mutated kinase deficiency exacerbates left ventricular dysfunction and remodeling late after myocardial infarction. Am J Physiol Heart Circ Physiol. (2016) 311:H445–52. 10.1152/ajpheart.00338.201627288435

Y EspachA LochnerH StrijdomB Huisamen. ATM protein kinase signaling, Type 2 diabetes and cardiovascular disease. Cardiovasc Drugs Ther. (2015) 29:51–8. 10.1007/s10557-015-6571-z25687661

[Back]

Figure 1.

Comparison of GGT [U/L] between A-T patient <12 years of age (n = 127) and ≥12 years of age (n = 156). Graph is shown as logarithmic scale p < 0.0001.

[Back]

[Back]

Figure 2.

Comparison of ALT [U/L] between A-T patient <12 years of age (n = 138) and ≥12 years of age (n = 164). Graph is shown as logarithmic scale p < 0.0001.

[Back]

[Back]

Figure 3.

Individual course of GGT with age, the scattered area is the normal range for GGT.

[Back]

[Back]

Figure 4.

Individual course of ALT with age, the scattered area is the normal range for ALT.

[Back]

[Back]

Table 1.

Patients' characteristics.

Group 1:
<12 years
n = 37
Group 2
≥12 years
n = 30
P-value

Age*
[years]
6.13 ± 2.8
18.4 ± 5
<0.0001

KAS
[points]
12.92 ± 0.86
n = 55
23.76 ± 0.43
n = 38
<0.0001#

AFP
[ng/dl]
226.8 ± 20.87
n = 95
565.1 ± 24.30
n = 137
<0.0001#

GGT
[U/l]
12.98 ± 0.41
n = 117
149.5 ± 10.99
n = 153
<0.0001#

ALT
[U/l]
23.52 ± 0.77
n = 125
87.83 ± 5.31
n = 161
<0.0001#

AST
[U/l]
37.92 ± 0.75
n = 126
59.72 ± 3.52
n = 163
p > 0.05#

TAG
[mg/dl]
84.39 ± 8.0
n = 31
251.8 ± 22.24
n = 60
<0.0001#

Cholesterol
[mg/dl]
176.3 ± 5.13
n = 32
212.7 ± 7.91
n = 57
<0.05#

CRP
[mg/dl]
0.16 ± 0.03
n = 108
0.27 ± 0.04
n = 116
<0.05#

Mean and SD of all quantifications are shown, n, Number of quantifications.

*. Age at start of investigations;

#. Group comparisons with p-values used the geometric mean of longitudinal data in each patient.

[Back]

[Back]

Table 2.

Linear Regression of AFP, GGT, ALT, AST, KAS, TAG, cholesterol, and CRP with age.

| Parameter | r | P
Age | AFP | 0.64 | <0.0001#
| GGT | 0.82 | <0.0001#
| ALT | 0.63 | <0.0001#
| AST | 0.24 |
| KAS | 0.76 | <0.0001*
| TAG | 0.50 | 0.0026#
| Cholesterol | 0.46 | 0.0069#
| CRP | 0.38 | 0.0051#

Correlation between age and AFP, GGT, ALT, AST, KAS, TAG, cholesterol, and CRP are shown, significant correlations could be shown for AFP, GGT, ALT, TAG, and KAS.

#. Correlations and p-values were calculated according to the geometric mean of the longitudinal data in each patient.

*. Correlation and p-value were calculated according to the arithmetic mean of the longitudinal data in each patient.

[Back]

[Back]

Figure 5.

Liver enzyme elevation in percent of affected patients with age.

[Back]

[Back]

Table 3.

Dataset on evolution of liver enzymes with age.

Age [years]
0-11
12
13
14
15
16
17
18
19
20-38

Measurements
n =
143
12
11
11
8
18
16
25
10
40

Patients
n =
37
10
9
8
6
11
14
14
8
14

Liver enzymes normal [%]
100
90
(9/10)
33.3
(3/9)
37.5
(3/8)
33.3
(2/6)
27.3
(3/11)
21.4
(3/14)
14.3
(2/14)
12.5
(1/8)
7.1
(1/14)

Liver enzymes elevated [%]
0
10
(1/10)
66.7
(6/9)
62.5
(5/8)
66.7
(4/6)
72.7
(8/11)
78.6
(11/14)
85.7
(12/14)
87.5
(7/8)
92.9
(13/14)

The dataset shows the percentage of patients showing elevated liver enzymes with age. While before puberty (group 1, <12 years of age) hardly any patient has abnormal liver enzymes, there is an increase after the 12th year of life (group 2). Also compare to Figure 5.

[Back]